Patents by Inventor Mei-Mei Tsai
Mei-Mei Tsai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8895008Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: GrantFiled: May 10, 2013Date of Patent: November 25, 2014Assignee: Amgen Inc.Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Patent number: 8541201Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: GrantFiled: July 19, 2011Date of Patent: September 24, 2013Assignee: Amgen Inc.Inventors: Hosung Min, Kenneth W. Walker, Colin V. Gegg, Francesco Galimi, Jeonghoon Sun, Mei-Mei Tsai
-
Publication number: 20130236457Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: ApplicationFiled: May 10, 2013Publication date: September 12, 2013Applicant: Amgen Inc.Inventors: Frank J. CALZONE, Rajendra V. DESHPANDE, Mei-Mei TSAI
-
Patent number: 8460662Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: GrantFiled: March 28, 2012Date of Patent: June 11, 2013Assignee: Amgen Inc.Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Publication number: 20120288507Abstract: The present invention relates to binding agents for WISE, and includes methods for their manufacture and use.Type: ApplicationFiled: December 17, 2010Publication date: November 15, 2012Applicant: Amgen Inc.Inventors: Xueming Qian, Aaron George Winters, Michelle Hortter, Kevin Graham, Mei-Mei Tsai
-
Patent number: 8309092Abstract: The present invention relates to binding agents for WISE, and includes for their manufacture and use.Type: GrantFiled: September 15, 2011Date of Patent: November 13, 2012Assignee: Amgen Inc.Inventors: Xueming Qian, Kevin Graham, Grant Shimamoto, Barbara S. Tipton, Mei-Mei Tsai, Aaron George Winters, Li Zhang
-
Publication number: 20120237516Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: ApplicationFiled: March 28, 2012Publication date: September 20, 2012Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Patent number: 8168409Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: GrantFiled: November 24, 2010Date of Patent: May 1, 2012Assignee: Amgen Inc.Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Publication number: 20120003237Abstract: The present invention relates to binding agents for WISE, and includes for their manufacture and use.Type: ApplicationFiled: September 15, 2011Publication date: January 5, 2012Applicant: AMGEN INC.Inventors: Xueming QIAN, Kevin Graham, Grant Shimamoto, Barbara S. Tipton, Mei-Mei Tsai, Aaron George Winters, Li Zhang
-
Publication number: 20110275122Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: ApplicationFiled: July 19, 2011Publication date: November 10, 2011Applicant: AMGEN INC.Inventors: Hosung MIN, Kenneth W. WALKER, Colin V. GEGG, JR., Francesco GALIMI, Jeonghoon SUN, Mei-Mei TSAI
-
Patent number: 8043620Abstract: The present invention relates to binding agents for WISE, and includes for their manufacture and use.Type: GrantFiled: November 21, 2008Date of Patent: October 25, 2011Assignee: Amgen Inc.Inventors: Xueming Qian, Kevin Graham, Grant Shimamoto, Barbara S. Tipton, Mei-Mei Tsai, Aaron George Winters, Li Zhang
-
Patent number: 7981425Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: GrantFiled: June 18, 2007Date of Patent: July 19, 2011Assignee: Amgen Inc.Inventors: Hosung Min, Kenneth W. Walker, Colin V. Gegg, Jr., Francesco Galimi, Jeonghoon Sun, Mei-Mei Tsai
-
Publication number: 20110089277Abstract: A compact manual shredder includes : a housing, being a column type tube body, constituted by upper and lower shells covered with each other, the upper shell being disposed with a paper entrance, the lower shell being disposed with a paper outlet and a pair of interlaced and side-by-side fragmentation cutters being configured inside the housing; and a transmission device, having a rotating unit disposed on one end of said housing and a gear train, two ends thereof being respectively coupled to the cutter pair and the rotating unit. Whereby, the rotating unit of the transmission device drives the gear train to rotate, and further drives the cutters to cut paper into fragments.Type: ApplicationFiled: March 30, 2010Publication date: April 21, 2011Inventors: Hsuan-Yu Chao, Mei-Mei Tsai
-
Publication number: 20110070615Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-1R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: ApplicationFiled: November 24, 2010Publication date: March 24, 2011Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Patent number: 7871611Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: GrantFiled: December 20, 2005Date of Patent: January 18, 2011Assignee: Amgen Inc.Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Publication number: 20090285824Abstract: The present invention provides compositions and methods relating to or derived from anti-IGF-1R antibodies. In particular embodiments, the invention provides fully human, humanized, or chimeric anti-IGF-1R antibodies that bind human IGF-R, IGF-1R-binding fragments and derivatives of such antibodies, and IGF-1R-binding polypeptides comprising such fragments. Other embodiments provide nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having IGF-1R-related disorders or conditions.Type: ApplicationFiled: December 20, 2005Publication date: November 19, 2009Applicant: AMGEN INC.Inventors: Frank J. Calzone, Rajendra V. Deshpande, Mei-Mei Tsai
-
Publication number: 20090130114Abstract: The present invention relates to binding agents for WISE, and includes for their manufacture and use.Type: ApplicationFiled: November 21, 2008Publication date: May 21, 2009Inventors: Xueming Qian, Kevin Graham, Grant Shimamoto, Barbara S. Tipton, Mei-Mei Tsai, Aaron George Winters, Li Zhang
-
Publication number: 20080070840Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.Type: ApplicationFiled: June 18, 2007Publication date: March 20, 2008Inventors: Hosung Min, Kenneth Walker, Colin Gegg, Francesco Galimi, Jeonghoon Sun, Mei-Mei Tsai
-
Patent number: 7084257Abstract: Selective binding agents of interferon-gamma (IFN?) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to IFN? and may be used to prevent or treat conditions relating to autoimmune and inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis. Nucleic acid molecules encoding said antibodies and antigen binding domains, and expression vectors and host cells for the production of same are also provided.Type: GrantFiled: October 5, 2001Date of Patent: August 1, 2006Assignee: Amgen Inc.Inventors: Rajendra V. Deshpande, Mei-Mei Tsai
-
Publication number: 20030099647Abstract: Selective binding agents of interferon-gamma (IFN&ggr;) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to IFN&ggr; and may be used to prevent or treat conditions relating to autoimmune and inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis. Nucleic acid molecules encoding said antibodies and antigen binding domains, and expression vectors and host cells for the production of same are also provided.Type: ApplicationFiled: October 5, 2001Publication date: May 29, 2003Inventors: Rajendra V. Deshpande, Mei-Mei Tsai